Novo Touts Diabetes R&D As Ozempic Faces Lilly Challenger
Amid Continued Obesity Lag
The Danish major highlighted a spate of diabetes pipeline updates during its second quarter earnings as blockbuster drug Ozempic grappled with a new rival in the shape of Lilly’s Mounjaro.
You may also be interested in...
Lilly Preparing For Increasing Mounjaro Demand On Top Of Solid Launch
The pharma is increasing its manufacturing capacity for tirzepatide, mindful of its potential in a second indication of obesity and the supply issues faced by competitor Novo Nordisk.
Europe’s Big Pharma Sails On Serenely Despite Choppy Economic Waters
The continent's pharmaceutical sector enjoyed another robust quarter with increased productivity, and price increases, softening the blow of rising energy costs and other challenges across the supply chain.
As Lilly’s Realized Sales Prices Drop, Ricks Reiterates Criticism Of US Drug Price Plan
With Lilly’s sales narrative hampered by global price pressures, Lilly CEO David Ricks again criticized drug price negotiation proposals before Congress. Mounjaro launch offers a bright spot, exceeding projections.